- If you are wondering whether Regeneron Pharmaceuticals at around US$766 per share still offers value, the answer depends on how you look at what the market is pricing in today.
- The stock recently closed at US$766.02, with returns of 2.7% over 7 days, 3.3% over 30 days, a 1.3% decline year to date, and 28.4% over the last year, which gives you a mixed snapshot of recent sentiment.
- Alongside these moves, investors have been tracking broader sector developments and company specific updates that shape expectations for Regeneron’s pipeline and competitive position. This context matters because valuation work is ultimately about how the market weighs that information against the current share price.
- On Simply Wall St’s 6 point valuation framework, Regeneron scores 4. Next you will see how traditional methods like P/E multiples and discounted cash flow compare, followed by a more holistic way to think about valuation at the end of the article.
Find out why Regeneron Pharmaceuticals’s 28.4% return over the last year is lagging behind its peers.
Approach 1: Regeneron Pharmaceuticals Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model takes estimates of the cash a company could generate in the future and discounts those amounts back to what they might be worth today. It is essentially asking what an investor would pay now for those projected cash flows in $.
For Regeneron Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $3.94b. Analyst and extrapolated projections in this model suggest free cash flow reaching about $11.02b by 2035, with interim estimates such as $5.05b in 2026 and $8.38b in 2030, all expressed before discounting.
After discounting the 10 year stream of projected cash flows and estimating value beyond that period, this model arrives at an intrinsic value of about $1,991.55 per share. When this output is compared with the recent share price around $766, it implies the stock is about 61.5% undervalued under these assumptions.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Regeneron Pharmaceuticals is undervalued by 61.5%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.
REGN Discounted Cash Flow as at Apr 2026
Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Regeneron Pharmaceuticals.
Approach 2: Regeneron Pharmaceuticals Price vs Earnings
For profitable companies, the P/E ratio is a practical way to think about value because it links the share price directly to the earnings that support it. What counts as a “normal” or “fair” P/E often reflects how much growth investors expect and how much risk they feel they are taking on for those earnings.
Regeneron currently trades on a P/E of 17.45x. That sits in line with the broader Biotechs industry average of about 17.45x and below the peer average of 23.30x, so the market is not assigning a premium multiple relative to peers.
Simply Wall St’s Fair Ratio for Regeneron is 25.21x. This is a proprietary estimate of what P/E might be appropriate after accounting for factors such as earnings growth profile, industry, profit margins, market capitalization and company specific risks. Because it adjusts for these company characteristics, the Fair Ratio can offer a more tailored anchor point than a simple peer or industry comparison. Relative to this Fair Ratio, Regeneron’s current P/E of 17.45x sits meaningfully lower, which suggests the shares may be undervalued on this metric.
Result: UNDERVALUED
NasdaqGS:REGN P/E Ratio as at Apr 2026
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.
Upgrade Your Decision Making: Choose your Regeneron Pharmaceuticals Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as a simple way for you to attach a clear story about Regeneron Pharmaceuticals to the numbers you see, by linking your view of its products, competition and risks to a forecast for revenue, earnings and margins, and then to a fair value that can be compared with the current share price.
On Simply Wall St’s Community page, Narratives are available as an easy tool used by millions of investors. You can pick or adapt a view that fits your own expectations and immediately see whether that story points to a Fair Value above or below today’s price, which in turn can help you decide whether you see the stock as potentially attractive or fully priced.
These Narratives update automatically when new earnings, product news or regulatory developments are added. Your fair value view keeps changing in line with fresh information rather than staying frozen at the time you first ran the numbers.
For Regeneron, one Narrative might lean toward the lower Fair Value around US$730, focusing on pricing pressure, biosimilars and concentration in key drugs. Another might lean toward the higher Fair Value around US$1,030.49, focusing on Dupixent growth, EYLEA HD, oncology assets and a broad late stage pipeline. Your task is to decide which story, or a point between them, best matches what you believe is realistic.
For Regeneron Pharmaceuticals however we will make it really easy for you with previews of two leading Regeneron Pharmaceuticals Narratives:
🐂 Regeneron Pharmaceuticals Bull Case
Fair value in this narrative: US$873.78 per share
Implied discount vs last close of US$766.02: about 12.3% undervalued
Modelled annual revenue growth: 9.20%
- Views Regeneron as benefiting from an expanding pipeline and wider Dupixent use, with more patients and indications supporting higher long term revenue and earnings.
- Sees manufacturing scale, R&D depth, and new areas such as obesity and cardiometabolic disease as important levers for margins and diversification beyond current blockbusters.
- Flags real risks around EYLEA competition, pricing pressure, and policy changes, but concludes that analysts’ consensus fair value of about US$874 still sits above the current share price.
🐻 Regeneron Pharmaceuticals Bear Case
Fair value in this narrative: US$730.00 per share
Implied premium vs last close of US$766.02: about 4.9% overvalued
Modelled annual revenue growth: 5.87%
- Focuses on pressure from global drug pricing reforms, biosimilars, and alternative therapies, particularly for EYLEA and EYLEA HD, which are important to current revenue.
- Assumes slower revenue growth and thinner margins as R&D costs stay high and competition for biologics intensifies, even with a broad late stage pipeline.
- Anchors on a fair value of about US$730 that sits slightly below the latest share price, reflecting the more cautious end of analyst expectations for growth and valuation.
If neither preview lines up with your own expectations, you can always adjust the assumptions, stress test both earnings paths, and see where your view of fair value lands between these two bookends using the full set of Regeneron narratives on Simply Wall St. To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Regeneron Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.
Do you think there’s more to the story for Regeneron Pharmaceuticals? Head over to our Community to see what others are saying!
NasdaqGS:REGN 1-Year Stock Price Chart
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Explore Now for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
